Last reviewed · How we verify
Regadenoson peripheral - peripheral
Regadenoson is an adenosine A2A receptor agonist that causes peripheral vasodilation to increase blood flow, used as a pharmacologic stress agent for cardiac imaging.
Regadenoson is an adenosine A2A receptor agonist that causes peripheral vasodilation to increase blood flow, used as a pharmacologic stress agent for cardiac imaging. Used for Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise, Peripheral vascular insufficiency and claudication (investigational).
At a glance
| Generic name | Regadenoson peripheral - peripheral |
|---|---|
| Sponsor | Lokien van Nunen |
| Drug class | Adenosine A2A receptor agonist |
| Target | Adenosine A2A receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Regadenoson selectively binds to adenosine A2A receptors on vascular smooth muscle cells in coronary and peripheral arteries, causing vasodilation and increased blood flow. This mimics the hemodynamic effects of exercise stress without the physical exertion, allowing assessment of coronary perfusion and cardiac function during imaging studies. The peripheral vasodilation effect is utilized in peripheral vascular applications to improve blood flow in compromised vascular beds.
Approved indications
- Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise
- Peripheral vascular insufficiency and claudication (investigational)
Common side effects
- Flushing
- Dyspnea
- Chest discomfort
- Headache
- Palpitations
- Hypotension
Key clinical trials
- Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System (NA)
- Allograft Dysfunction in Heart Transplant (PHASE4)
- An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD) (PHASE3)
- Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies (NA)
- Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR) (NA)
- Regadenoson and Adenosine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regadenoson peripheral - peripheral CI brief — competitive landscape report
- Regadenoson peripheral - peripheral updates RSS · CI watch RSS
- Lokien van Nunen portfolio CI